Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $56.88 USD
Change Today -0.96 / -1.66%
Volume 11.7M
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$57.35
Previous Close
$57.84
Day High
$57.36
Day Low
$56.57
52 Week High
01/13/15 - $63.62
52 Week Low
10/16/14 - $52.49
Market Cap
160.9B
Average Volume 10 Days
11.8M
EPS TTM
$2.01
Shares Outstanding
2.8B
EX-Date
03/12/15
P/E TM
28.3x
Dividend
$1.80
Dividend Yield
3.13%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, including antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

70,000 Employees
Last Reported Date: 02/27/15
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $3.2M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.5M
President of Global Human Health and Executiv...
Total Annual Compensation: $962.4K
Compensation as of Fiscal Year 2014.

merck & co. inc. (MRK) Key Developments

Merck and Newlink Genetics Corporation Announces Initiation of Third, Late-Stage, Clinical Trial of Their Ebola Vaccine Candidate rVSV-ZEBOV-GP

Merck and NewLink Genetics Corporation confirmed that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine candidate was originally developed by the Public Health Agency of Canada’s National Microbiology Laboratory and licensed to NewLink Genetics in 2010. On Nov. 24, 2014, Merck and NewLink Genetics announced an exclusive licensing and collaboration agreement for the investigational Ebola vaccine. The Phase II/III safety and effectiveness study, called STRIVE (Sierra Leone Trial to Introduce a Vaccine against Ebola) taking place in Sierra Leone will involve 6,000 health and other frontline workers and is being led by the Sierra Leone College of Medicine and Allied Health Sciences, Sierra Leone Ministry of Health and Sanitation, and the U.S. Centers for Disease Control and Prevention (CDC). The Merck and NewLink rVSV-ZEBOV-GP vaccine candidate is now included in three large-scale clinical trials currently underway in West Africa. In addition to the trial in Sierra Leone, these trials are: The Partnership for Research on Ebola Vaccines in Liberia (PREVAIL): Led by a Liberia-U.S. clinical research partnership and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), PREVAIL was designed to enroll approximately 27,000 healthy men and women aged 18 years and older. This randomized, controlled Phase II/III study to evaluate safety and efficacy, involves rVSV-ZEBOV-GP and another experimental Ebola vaccine. Based on declining Ebola virus incidence in Liberia, the trial leaders have determined that it is scientifically appropriate to expand the trial to additional sites in other West African countries. Discussions are underway to explore that possibility, but the trial has not yet expanded outside of Liberia. Phase III study in Guinea: The World Health Organization (WHO), the Health Ministry of Guinea, Médecins sans Frontières (MSF), Epicentre and The Norwegian Institute of Public Health have initiated a safety and effectiveness study investigating Merck’s and NewLink’s rVSV-ZEBOV-GP, the vaccine candidate that was selected by the WHO and study partners to be assessed first in this study.

Merck & Co. Inc. Presents at ChinaBio Partnering Forum 2015, Apr-16-2015 09:30 AM

Merck & Co. Inc. Presents at ChinaBio Partnering Forum 2015, Apr-16-2015 09:30 AM. Venue: Kerry Hotel, Pudong, Shanghai, China.

Advaxis, Inc. and Merck Announces Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA

Advaxis, Inc. and Merck announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that AdvaxisLm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination. KEYNOTE-046 is a multicenter, dose determining, open-label Phase 1/2 study designed to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with KEYTRUDA in approximately 51 mCRPC patients. Part A of the study will be a dose escalating study designed to establish the maximum tolerated dose of ADXS-PSA as a monotherapy. Part B will consist of a dose escalating trial of ADXS-PSA in combination with KEYTRUDA, followed by an expansion cohort phase. The primary objective is to evaluate safety and tolerability of the two immunotherapies, with the secondary objective to evaluate anti-tumor activity and progression-free survival (PFS).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $56.88 USD -0.96

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $161.71 USD -4.18
Amgen Inc $163.58 USD -3.29
Gilead Sciences Inc $101.38 USD -1.96
L'Oreal SA €176.30 EUR -2.45
Pfizer Inc $35.04 USD -0.15
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 14.0x
Price/Sales 3.9x
Price/Book 3.3x
Price/Cash Flow 13.5x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.